Role of TRIM2 and SIRPA in New World arenavirus entry
Official title: The role of TRIM2 and SIRPA in New World Arenavirus entry
Funded at University of Illinois at Chicago · NIH-11577753 · Data updated 2026-11-12
A study to understand how certain human genes help prevent the entry of dangerous New World arenaviruses into cells, with the goal of guiding future therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | May 23, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $68,049 |
| NIH project number | 3R01AI159290-05S1 |
| Project ID | NIH-11577753 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to patients directly; this is a basic science study using cellular systems.
✕Less likely to help
Direct patient benefit is not expected during the laboratory research phase.
What this research studies
This project looks at how TRIM2 and SIRPA influence the way New World arenaviruses enter human cells. Researchers will use cellular models and pseudotyped viruses to identify host proteins that block infection and to map the entry process after the virus is inside a cell’s acidic compartments. By uncovering these mechanisms, the work aims to point to potential therapeutic targets that could stop virus spread early in infection. The findings could inform strategies to protect people in regions where these arenaviruses are a risk and to improve responses to outbreaks. The study builds on prior siRNA screening that linked TRIM2 to reduced viral entry, expanding the network of host factors involved in infection.
Why it matters
Potential benefit: Could lead to new antiviral strategies that prevent or limit infection by dangerous arenaviruses.
How similar studies have gone: Previous work shows host factors like TRIM2 can influence viral entry, supporting the potential relevance of these findings.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Ross, Susan R — University of Illinois at Chicago
- Study coordinator: Ross, Susan R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.